Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.